{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '11.10.3. Informed Consent Process', '119', '11.10.4. Data Protection', '120', '11.10.5. Committees Structure', '120', '11.10.6.', 'Publication Policy', '120', '11.10.7. Dissemination of Clinical Study Data', '121', '11.10.8. Data Quality Assurance', '121', '11.10.9.', 'Source Documents', '122', '11.10.10. Study and Site Closure', '122', '11.11. Appendix 11: Division of AIDS Table for Grading the Severity of', 'Adult and Pediatric Adverse Events Version 2.1, March 2017', '123', '11.12. Appendix 12: CDC Classification for HIV-1 Infection (2014)', '153', '11.13. Appendix 13: Country-specific requirements', '155', '11.14. Appendix 14: COVID-19 Pandemic and Clinical Trial Continuity', '157', '11.14.1. Changes to Study Visits and Study Procedures', '157', '11.14.2. Changes to Informed Consent', '158', '11.14.3. Direct-To-Patient (DTP) Shipment of Study IP', '159', '11.14.4. COVID-19 Experimental Agents', '160', '11.14.5. COVID-19 Specific Data Capture', '160', '11.14.5.1. Capturing COVID-19 Specific Protocol', 'Deviations', '160', '11.14.5.2. Capturing COVID-19 Specific AEs and SAEs', '161', '11.15. Appendix 15: Protocol Amendment History', '164', '10']['2017N331008_06', 'CONFIDENTIAL', '208090', '1.', 'PROTOCOL SUMMARY', '1.1.', 'Synopsis', 'Protocol Title: A Phase III, randomized, multicenter, open-label, non-inferiority study', 'evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine', 'fixed dose combination in HIV-1 infected adults who are virologically suppressed', 'Short Title: A Phase III, randomized, multicenter, open-label, non-inferiority study', 'evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine', 'fixed dose combination in HIV-1 infected adults who are virologically suppressed', 'Rationale: This study is being conducted to establish if adults living with human', 'immunodeficiency virus type 1 (HIV-1) with virologic suppression on a >3 drug current', 'antiretroviral regimen (CAR) remain suppressed upon switching to', 'dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC). This study will also', 'provide important information regarding the safety and health related quality of life with', 'this two-drug regimen. This trial is designed to demonstrate the non-inferior antiviral', 'activity of switching to DTG/3TC FDC once daily compared to continuation of CAR', 'over 48 weeks.', '11']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Objectives and Endpoints:', 'Objectives', 'Enpoints', 'Primary', 'To demonstrate the non-inferior antiviral activity', 'Virologic failure endpoint as per Food and Drug', 'of switching to DTG/3TC FDC once daily', 'Administration (FDA) snapshot category at', 'compared to continuation of CAR over 48', 'Week 48', 'weeks in virologically suppressed adults living', 'with HIV-1', 'Secondary', 'To demonstrate the antiviral activity of switching', 'Proportion of participants with plasma HIV-1', 'to DTG/3TC FDC once daily compared to', 'RNA <50 c/ml at Week 48 using the Snapshot', 'continuation of CAR over 48 weeks', 'algorithm for the intent-to-treat exposed (ITT-E)', 'population', 'To evaluate the antiviral activity of switching to', 'Virologic failure endpoint as per FDA', 'DTG/3TC FDC once daily compared to', 'snapshot category at Week 24', 'continuation of CAR over 24 weeks', 'Proportion of participants with plasma HIV-1', 'RNA <50 c/ml at Week 24 using the', 'Snapshot algorithm for the ITT-E population', 'To evaluate the immune effects of DTG/3TC', 'Change from Baseline in CD4+ cell count', 'FDC once daily compared to continuation of', 'and in CD4+/CD8+ cell counts ratio at', 'CAR', 'Weeks 24 and 48', 'Incidence of disease progression (HIV-', 'associated conditions, acquired', 'immunodeficiency syndrome [AIDS], and', 'death) through Weeks 24 and 48', 'To evaluate the safety and tolerability of', 'Incidence and severity of adverse events', 'DTG/3TC FDC once daily compared to CAR', '(AEs) and laboratory abnormalities', 'over time', 'Proportion of participants who discontinue', 'treatment due to AEs', 'To evaluate the safety and tolerability of', 'Incidence and severity of AEs and', 'DTG/3TC FDC once daily in those with', 'laboratory abnormalities', 'creatinine clearance of between', 'Proportion of participants who discontinue', '30-49 mL/min/1.73m\u00b2 compared to those with a', 'treatment due to AEs', 'creatinine clearance of >50 mL/min/1.73m\u00b2', 'To evaluate the effects of DTG/3TC FDC once', 'Change from Baseline in fasting lipids at Weeks', 'daily on fasting lipids over time compared to', '24 and 48', 'CAR', 'To assess viral resistance in participants', 'Incidence of observed genotypic and', 'meeting Confirmed Virologic Withdrawal (CVW)', 'phenotypic resistance to antiretrovirals (ARVs)', 'Criteria', 'for participants meeting CVW Criteria', '12']\n\n###\n\n", "completion": "END"}